Merck, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: $295.3B

Website: http://www.merck.ph

Clinical Trials

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Phase 3

Recruiting

Conditions: Solid Tumors
Hematologic Malignancies

Interventions: Drug: Pembrolizumab
Drug: Lenvatinib
Drug: Olaparib
Biological: MK-4280A
Drug: MK-4280
Drug: Standard of Care (SOC)

First Posted Date: 2018-04-03

Last Posted Date: 2025-05-16

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 3500

Registration Number: NCT03486873

Locations: 🇵🇷
Ad-Vance Medical Research-Research ( Site 1151), Ponce, Puerto Rico
🇵🇷
FDI Clinical Research ( Site 1152), San Juan, Puerto Rico
🇵🇷
UPR Comprehensive Cancer Center ( Site 1150), San Juan, Puerto Rico

and more 660 locations

V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002)

Phase 2

Completed

Conditions: Cytomegalovirus (CMV) Infections

Interventions: Biological: V160
Drug: Placebo

First Posted Date: 2018-04-03

Last Posted Date: 2024-01-23

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 2200

Registration Number: NCT03486834

Locations: 🇨🇦
PrimeHealth Clinical Research ( Site 0070), Toronto, Ontario, Canada
🇺🇸
St Michaels Med Center ( Site 0285), Newark, New Jersey, United States
🇺🇸
Indago Research & Health Center, Inc ( Site 0007), Hialeah, Florida, United States

and more 92 locations

Study of Gefapixant (MK-7264) in Adult Japanese Participants With Unexplained or Refractory Chronic Cough (MK-7264-033)

Phase 2

Completed

Conditions: Chronic Cough

Interventions: Drug: Placebo
Drug: Gefapixant 45 mg

First Posted Date: 2018-03-29

Last Posted Date: 2019-10-17

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 23

Registration Number: NCT03482713

Locations: 🇯🇵
Yokohama City Minato Red Cross Hospital ( Site 3306), Yokohama, Kanagawa, Japan
🇯🇵
Tsumura Cardiovascular-internal-medicine Clinic ( Site 3314), Kakogawa, Hyogo, Japan
🇯🇵
Saiseikai Kanazawa Hospital ( Site 3337), Kanazawa, Ishikawa, Japan

and more 13 locations

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)

Phase 3

Completed

Conditions: Pneumococcal Infections

Interventions: Biological: Prevnar 13™
Biological: V114
Biological: PNEUMOVAX™23

First Posted Date: 2018-03-29

Last Posted Date: 2022-05-05

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 302

Registration Number: NCT03480802

Locations: 🇵🇪
Investigaciones Medicas en Salud - INMENSA ( Site 0041), Lima, Peru
🇫🇷
Hopital Gabriel Montpied ( Site 0084), Clemont Ferrand, France
🇺🇸
Triple O Research Institute, P.A. ( Site 0011), West Palm Beach, Florida, United States

and more 10 locations

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)

Phase 3

Completed

Conditions: Pneumococcal Infections

Interventions: Biological: Prevnar 13™
Biological: V114
Biological: PNEUMOVAX™23

First Posted Date: 2018-03-29

Last Posted Date: 2021-11-02

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 652

Registration Number: NCT03480763

Locations: 🇺🇸
Rapid Medical Research, Inc. ( Site 0119), Cleveland, Ohio, United States
🇺🇸
University of Texas Medical Branch at Galveston ( Site 0127), Galveston, Texas, United States
🇺🇸
Texas Center For Drug Development ( Site 0107), Houston, Texas, United States

and more 19 locations

Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)

Phase 2

Completed

Conditions: Solid Tumors
Non-small Cell Lung Cancer
Castration Resistant Prostate Cancer
Microsatellite Stable Colorectal Cancer

Interventions: Drug: Navarixin
Biological: Pembrolizumab

First Posted Date: 2018-03-22

Last Posted Date: 2024-08-28

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 107

Registration Number: NCT03473925

Locations: 🇦🇺
Peter MacCallum Cancer Centre ( Site 0023), Melbourne, Victoria, Australia
🇺🇸
Honor Health ( Site 0005), Scottsdale, Arizona, United States
🇺🇸
Florida Cancer Specialists ( Site 0003), Sarasota, Florida, United States

and more 11 locations

A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-027)

Phase 3

Completed

Conditions: Chronic Cough

Interventions: Drug: Placebo
Drug: Gefapixant

First Posted Date: 2018-02-28

Last Posted Date: 2021-06-16

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 732

Registration Number: NCT03449134

Locations: 🇺🇸
Research Solutions of Arizona PC ( Site 0036), Litchfield Park, Arizona, United States
🇺🇸
Medical Research of AZ ( Site 0060), Scottsdale, Arizona, United States
🇦🇷
InAER Investigaciones en Alergia y Enfermedades Respiratorias ( Site 0324), Caba, Buenos Aires, Argentina

and more 153 locations

A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)

Phase 3

Completed

Conditions: Chronic Cough

Interventions: Drug: Placebo
Drug: Gefapixant 15 mg BID
Drug: Gefapixant 45 mg BID

First Posted Date: 2018-02-28

Last Posted Date: 2021-09-02

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1317

Registration Number: NCT03449147

Locations: 🇺🇸
Bethesda Allergy Asthma and Research Center LLC ( Site 0019), Bethesda, Maryland, United States
🇺🇸
Atlanta Allergy & Asthma Clinic PA ( Site 0029), Stockbridge, Georgia, United States
🇺🇸
University of Missouri ENT & Allergy Center ( Site 0066), Columbia, Missouri, United States

and more 168 locations

Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)

Phase 3

Completed

Conditions: CMV Disease

Interventions: Drug: Letermovir
Drug: Valganciclovir
Drug: Acyclovir (ACV)
Drug: Placebo to ACV
Drug: Placebo to LET
Drug: Placebo to VGCV

First Posted Date: 2018-02-23

Last Posted Date: 2023-07-28

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 601

Registration Number: NCT03443869

Locations: 🇺🇸
University of Chicago ( Site 0251), Chicago, Illinois, United States
🇺🇸
Brigham & Women's Hospital ( Site 0244), Boston, Massachusetts, United States
🇺🇸
The Ohio State University Wexner Medical Center ( Site 0264), Columbus, Ohio, United States

and more 91 locations

Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

Phase 3

Active, not recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Biological: Pembrolizumab
Drug: Placebo
Drug: Cisplatin
Drug: Gemcitabine
Drug: Pemetrexed

First Posted Date: 2018-02-07

Last Posted Date: 2024-12-03

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 797

Registration Number: NCT03425643

Locations: 🇺🇸
UPMC Hillman Cancer Centers ( Site 0041), Pittsburgh, Pennsylvania, United States
🇺🇸
PPG-Oncology ( Site 0043), Fort Wayne, Indiana, United States
🇺🇸
Ingalls Memorial Hospital ( Site 0044), Harvey, Illinois, United States

and more 224 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy